US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years

A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.